What Survivorship Looks Like

Earlier this month, we honored National Cancer Survivors Day and reflected on the courage, resilience, and humanity at the heart of our community.


Survivorship after a stomach cancer diagnosis is not a single moment. For many, it begins on the day of an initial diagnosis, and it reshapes everything: how the body feels, how identity shifts, what "normal" looks like.

This month, we asked our community: When does survivorship begin? What surprises you most? What would you tell someone just starting their journey?


A response that moved us deeply came from stage 4 survivor and author Joy Huber, who wrote, "You beat cancer in the way you live forward from that moment." And even on the hardest days, she says, you get to choose how you respond to it all.


That wisdom lives at the core of everything we do at the Gastric Cancer Foundation - from our Your New Normal video series that gives voice to what patients and survivors actually experience, to our online community of patients and caregivers, our clinical trial navigator, and the research we fund to create and support more survivors in the years to come. Every resource is built for this community, honoring every step of the journey.

 

Stomach Cancer Experts Share Optimism After ASCO 2026

Three top stomach cancer experts came away from the American Society of Clinical Oncology (ASCO) Annual Conference in Chicago earlier this month feeling optimistic about several promising treatments, they said during a webinar on June 11.


The webinar was hosted by seven organizations dedicated to advancing cures for gastric cancer, including the Gastric Cancer Foundation. The discussion was moderated by former Gastric Cancer Foundation grantee Samuel Klempner, MD, of Massachusetts General Hospital and Harvard Medical School. The panel included Frank Blandon, a stomach cancer patient who weighed in on his experiences being treated for the past two years.


The panelists covered a range of advances discussed at ASCO, including new surgical regimens, combination treatments and novel drugs. Panelist Yelena Janjigian, MD, of Memorial Sloan Kettering Cancer Center was particularly impressed by results from a trial of Ziihera (zanidatamab) combinations in the first-line treatment of patients with HER2-positive gastric cancer. Data shared at ASCO showed that combining Ziihera with Tevimbra (tislelizumab), a PD-1 immune checkpoint inhibitor and chemotherapy significantly improved progression-free survival regardless of whether patients’ tumors tested positive or negative for PD-L1—a tumor biomarker commonly used to determine patients’ likelihood to respond to immunotherapy.


Webinar panelist Elena Elimova, MD, of the University of Toronto—who is one of the investigators in the Ziihera trial—suggested that the positive results “open this treatment option for actually all comers. So that is what’s new and that’s what’s exciting.” She added that some gastric cancer patients she has treated as part of the trial have been survivors for more than five years.


The panelists also expressed optimism about emerging experimental treatments that target other genetic abnormalities in tumors. They include savolitinib, which inhibits a tumor-driving receptor called MET. An estimated 5% of gastric cancer patients have MET-positive tumors. In a phase 2 trial in China that was presented at ASCO, savolitinib shrank tumors in one-third of patients—results that could pave the way for future studies.


Klempner said he’s optimistic that the combination of effective targeted drugs and improved access to next-generation genetic sequencing that can identify rare tumor biomarkers like MET will ultimately improve the prognosis for gastric cancer patients. “This was the…largest trial with an active [MET-targeted drug] that worked,” Klempner said. “Better drugs, better patient selection—it’s a pretty good recipe to get to success.”


If you missed the live event, the full recording is available now. 

Watch the webinar >>


This was the first in a planned series of educational webinars co-hosted by a collaborative including Debbie's Dream Foundation, Gastric Cancer Foundation, GI Cancers Alliance, Hope for Stomach Cancer, My Gut Feeling, No Stomach for Cancer, and Stomach Cancer UK. Stay tuned for our next webinar following the 2026 ESMO Gastrointestinal Cancers Congress in July.

 

Share Your Insights: Shape the Future of Gastric Cancer Foundation

On June 18, Executive Director Harriet Patterson, MPH hosted a Virtual Meet & Greet to hear directly from patients, survivors, caregivers, and community members about what matters most. Harriet shared, "It was great to meet and connect with members of our community. I look forward to future opportunities to get to know folks who are passionate about making an impact in the fight against stomach cancer."


Couldn't make it? We still want to hear from you. Reach out to us directly to share your story, ideas, or feedback. GCF is building a new Strategic Plan, and your voice can help us shape where we go next.

 
 

You are not alone. Our free online forum offers peer-to-peer support in a safe and confidential space.

 

Alternative Bean Hummus


Hans Rueffert is back in the kitchen with fellow no-stomach survivor Stacy Martin to make a creamy, garlicky tofu hummus that delivers big on flavor and nutrition, with none of the digestive drama. Hans shares his garlic confit trick, the case for nutritional yeast, and why this recipe is really just a starting point. Watch the episode and start building your own version.

 

Quick Links to Resources

 
 
Special Thanks to Our
National Sustaining Sponsors
 
Facebook  Twitter  Linkedin  Youtube  

larSpread the word. Share the Gastric Cancer Foundation Newsletter.

X Share This Email
LinkedIn Share This Email